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Can antibiotic prescribing for respiratory
infections be reduced?
Martin Gulliford, Mark Ashworth
T he growing threat of anti-microbial drug resistance(AMR) is attracting the atten-
tion of national governments and in-
ternational organisations. In the words
of Margaret Chan, Director-General of
the World Health Organization, “We
are hearing one alarm bell after
another.”1 This is apparent in primary
care, where the frequency of antibiotic-
resistant infections is increasing. The
emergence of AMR is a multifaceted
societal problem that requires action
from a range of actors, including the
pharmaceutical, agricultural and food
production industries.2 But it is the
health care sector, where antibiotics
are prescribed and patients with
resistant infections are seen, that the
impact of AMR is most acute. This is
especially relevant in Australia, where
antibiotic consumption is among the
highest of the OECD countries.3
Primary care accounts for nearly three-quarters of all antibiotic
prescribing in England, and respiratory tract infections (RTIs)
comprise the largest single group of indications for antibiotic
treatment.4 The article byMcCullough and colleagues in this issue
of theMJA reports on the use of antibiotics for treating respiratory
infections in Australia.5 Their study reveals that acute respiratory
infections account formore than half of all antibiotics prescribed in
primary care, but fewer than one-quarter of prescriptions for
antibiotics— and possibly as few as 11%— could be justiﬁedwith
reference to Australian prescribing guidelines.
The situation is similar in the United Kingdom, where general
practitioners prescribe antibiotics at about 52% of consultations for
self-limiting RTIs, including common colds, acute cough and
bronchitis, sore throat, otitis media, and rhinosinusitis,6 and with
little change in practice over the past two decades.7,8 Evidence from
randomised controlled trials indicate that antibiotics generally have
little if any effect on the severity or duration of symptoms in these
conditions, and treatment is frequently associated with unwanted
side effects, such as rashes and diarrhoea.9,10 Consequently, UK
guidelines recommend that a no-antibiotic prescribing strategy be
agreed with most patients who present with self-limiting RTIs.11
The widespread use of antibiotics also has the effect of medical-
ising conditions that are usually self-limiting and which most
patients could manage themselves. Giving a patient even one
antibiotic prescription greatly increases the likelihood that theywill
also visit a GP for future episodes of similar conditions.12
Prescribing an antibiotic may sometimes be motivated by the
perceived risk of complications. Antibiotic treatment is associated
with reduced risks of peritonsillar abscess after sore throat, and of
mastoiditis after otitis media, but these complications are so rare
that more than 4000 patients would need to be treated with anti-
biotics to prevent one case.13 We recently reported a study of 610
UK general practices, with 45.5 million person-years of follow-up
between 2005 and 2014.14 We estimated that if a general practice
with the UK average list size of 7000 patients reduced the propor-
tion of RTI consultations at which antibiotics were prescribed by
10%, it might see one additional case of pneumonia each year and
one of peritonsillar abscess each decade. Therewas no evidence that
mastoiditis, empyema,meningitis, intracranial abscess, or Lemierre
syndromeweremore frequent at low-prescribing practices. Current
evidence suggests that antibiotic prescribing is not justiﬁed on
safety grounds for most patients presenting with RTIs; GPs can use
existing guidelines to target patients who are at increased risk of
complications because of severity of illness, age or comorbidity.11
Physicians should be able to prescribe antibiotic therapywhen it is
necessary, and several approaches to promoting more effective
antibiotic stewardship in primary care are now being explored.
Deferred or delayed prescribing, in which a prescription is given
but onlyﬁlled if needed, is sometimes advocated, but this approach
may be less effective in reducing antibiotic use than a no-
prescribing strategy, while achieving similar patient satisfac-
tion.15 Point-of-care testing for biomarkers of bacterial infection
that enables targeted prescribing of antibiotics is being developed
as a strategy, but its effectiveness is not yet fully established, and it
may be difﬁcult to integrate into normal clinical practice.16
Behavioural insights are also being harnessed; for example,
sending high-prescribing GPs in England a personalised letter
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signed by the Chief Medical Ofﬁcer resulted in a 3% reduction in
antibiotic dispensing.17 A contractual ﬁnancial incentive (“quality
premium”) for meeting targets for reducing antibiotic prescribing
has been introduced by the English National Health Service, with
favourable initial results.18
If the alarmbells are to be dampened, reductions in national levels
of total antibiotic prescribing will be required. This might be
achievable, with the latest ﬁgures indicating that antibiotic pre-
scribing in primary care in England was 7.9% lower in 2015 than
in the preceding year.19 Sharing national data on successful
antibiotic campaigns is oneway to contribute to improving global
health.
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